Publications by authors named "Richard Buka"

Claim this Profile
T
Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England.
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J Curtis

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician Survey on the Management of Pulmonary Embolism in Pregnancy: Need for Guidance and Training.
Giulia Simini, Richard Buka, Daniel Kajita, Omar Mukhlif,

EJHaem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can health inequalities in sickle cell disease be addressed through novel therapies?
Stephen P Hibbs, Richard J Buka, Mary Shaniqua, Paul Greaves, John James

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics.
Phillip L R Nicolson, Samantha J Montague, Richard J Buka, Anthony Calvert, Jo-Ann I Sheppard

Br J Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in menstrual bleeding management during acute venous thromboembolism treatment: A review of UK practice and a call for clinical studies.
Eman Hassan, David Sutton, Richard J Buka, Gillian Lowe, Taran Nandra

Thromb Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Andexanet alfa: trials just leave us with more questions.
Richard J Buka

Res Pract Thromb Haemost· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-platelet factor 4 immunothrombotic syndromes.
Richard J Buka, Sue Pavord

Br J Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand': Journal of Thrombosis and Haemostasis, Volume 22, Issue 1, (January 2024) Pages 271-285.
Eleyna M Martin, Joanne C Clark, Samantha J Montague, Luis A Morán, Ying Di, Richard J Buka

J Thromb Haemost· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal drug reaction to andexanet alfa: a case report.
Richard J Buka, Mamidipudi T Krishna, David J Sutton

EJHaem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
Richard J Buka, David J Sutton, Phillip Lr Nicolson

J Thromb Thrombolysis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand.
Eleyna M Martin, Joanne C Clark, Samantha J Montague, Luis A Morán, Ying Di, Richard J Buka

J Thromb Haemost· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF4 activates the c-Mpl-Jak2 pathway in platelets.
Richard J Buka, Samantha J Montague, Luis A Moran, Eleyna M Martin, Alexandre Slater

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.
Asim Cengiz Akbulut, Ryanne A Arisz, Constance C F M J Baaten, Gaukhar Baidildinova, Aarazo Barakzie, Richard J Buka

Thromb Haemost· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual pathology: paraneoplastic sarcoidosis emerging at the time of progression from smouldering to symptomatic myeloma.
Muzna Aquil, Hannah Giles, Richard Buka, Fehmida Bano

BMJ Case Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease.
Richard J Buka, Noémi Roy, Phillip Lr Nicolson

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How will UK hospitals use andexanet alfa? A review of local protocols.
Paula Glancy, David J Sutton, Keith Gomez, Phillip L R Nicolson, Richard J Buka

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices.
Richard J Buka, David J Sutton

Blood Adv· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis.
Phyo Wint Wint Tun, Richard J Buka, Jane Graham, Peter Dyer

Br J Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HaemSTAR-Growing Experience From a National, Trainee-led Research Network.
Lydia Wilson, Andrew J Doyle, Emily Millen, Tom Bull, Tina Biss, Richard J Buka

Hemasphere· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Justin Loke, Richard Buka, Charles Craddock

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies?
Richard J Buka, Deepak Chandra, David J Sutton

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of paediatric eczema with narrowband ultraviolet light B therapy.
Manrup K Hunjan, Julia R Brockley, Richard Buka, Raakhee Ramesh

Photodermatol Photoimmunol Photomed· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in Human Anaphylaxis: A Critical Appraisal of Current Evidence and Perspectives.
Sarah C Beck, Thomas Wilding, Richard J Buka, Richard L Baretto, Aarnoud P Huissoon

Front Immunol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rota changes in acute and general internal medicine: delivering improved patient care and junior doctor training at the front and back door - acute medical unit placement blocks the way forward for Midland Met!
Richard Buka, Donna Best, Sarbjit Clare

Future Healthc J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis